Clinical Trials

Multiple Myeloma

NCT03710421 2026-04-15

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma

30 enrolled

Multiple Myeloma

NCT05336383 2026-04-15

Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma

30 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05623020 2026-04-15

MagnetisMM-6

1,116 enrolled

Multiple Myeloma

NCT07107529 2026-04-15

Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.

150 enrolled

Multiple Myeloma

NCT07455851 2026-04-15

A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

Phase 1/2 Recruiting

150 enrolled

Multiple Myeloma

NCT03412877 2026-04-14

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

BreastEndocrineGynecologicNETPlasma cellThoracic

285 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT06103838 2026-04-14

18F-Fluciclovine PET/CT in Multiple Myeloma

60 enrolled

Multiple Myeloma

NCT06182774 2026-04-14

Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma

570 enrolled

Multiple Myeloma

NCT06615479 2026-04-14

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

440 enrolled

Multiple Myeloma, Recurrence

NCT07030517 2026-04-14

A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma

Phase 4 Recruiting

75 enrolled

Multiple Myeloma

NCT07382739 2026-04-14

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

34 enrolled

Multiple Myeloma

NCT07409246 2026-04-14

A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

127 enrolled

Multiple Myeloma, Neoplasms

NCT07529782 2026-04-14

Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma

15 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03017820 2026-04-13

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

127 enrolled

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT04634552 2026-04-13

MonumenTAL-1

Other hematologic neoplasmPlasma cell

510 enrolled 2 FDA

Multiple Myeloma, Hematologic Neoplasms

NCT04847453 2026-04-13

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

24 enrolled

Immunoglobulin Light-chain Amyloidosis

NCT05201781 2026-04-13

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Phase 4 Recruiting

295 enrolled

Multiple Myeloma

NCT05438043 2026-04-13

A Study of Daratumumab

500 enrolled

Multiple Myeloma

NCT05552222 2026-04-13

MajesTEC-7

1,590 enrolled

Multiple Myeloma

NCT05652335 2026-04-13

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

180 enrolled

Amyloidosis, Multiple Myeloma, Recurrence

NCT06145581 2026-04-13

Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma

Phase NA Recruiting

25 enrolled

Multiple Myeloma

NCT06179888 2026-04-13

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

78 enrolled

Multiple Myeloma

NCT06433947 2026-04-13

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

130 enrolled

Multiple Myeloma

NCT06465316 2026-04-13

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

26 enrolled

Multiple Myeloma

NCT06483100 2026-04-13

Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance

65 enrolled

Multiple Myeloma

NCT06500884 2026-04-13

Talisman

210 enrolled

Multiple Myeloma

NCT06604715 2026-04-13

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

80 enrolled

Multiple Myeloma, Recurrence

NCT06669247 2026-04-13

COSTIMM

Phase 1/2 Recruiting

186 enrolled

Multiple Myeloma

NCT06768489 2026-04-13

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

140 enrolled

Multiple Myeloma

NCT06934044 2026-04-13

A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma

20 enrolled

Multiple Myeloma

NCT07032714 2026-04-13

MAGENTA

25 enrolled

Multiple Myeloma

NCT07149857 2026-04-13

CARTITUDE-10

60 enrolled

Multiple Myeloma

NCT07258511 2026-04-13

TRIlogy-4

400 enrolled

Multiple Myeloma

NCT07266441 2026-04-13

TRIlogy-3

157 enrolled